poisar

Stocks · News reference

Aclaris Therapeutics Announces Top Line Results from Phase 2 ADMIRATION Trial of Bosakitug

Fiscal.ai

Aclaris Therapeutics reported that its Phase 2 ADMIRATION trial evaluating bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis did not meet its primary endpoint.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading